Sees 2023 loss before income taxes ($726M)-($626M). Sees 2023 adjusted EBITDA ($25M)-$75M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EBS:
- Emergent BioSolutions Reports Third Quarter 2023 Financial Results
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
- Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
- Emergent BioSolutions appoints Fowler, DeGolyer to board of directors